Results 251 to 260 of about 230,151 (306)

CD30 as a Target Molecule in the Diagnosis and Therapy of Lymphomas

American Journal of Hematology, Volume 101, Issue 1, Page 110-128, January 2026.
ABSTRACT The tumor necrosis factor (TNF)‐receptor superfamily 8 receptor CD30 molecule is expressed in all tumor cells of Hodgkin lymphoma and anaplastic large cell lymphoma but is only weakly expressed in a small subset of large lymphoid cells in normal peripheral lymphoid tissues.
Harald Stein, Brunangelo Falini
wiley   +1 more source

Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature. [PDF]

Ann Hematol
Dai Y, Ai Y, Sun S, Tang M, Li J, Gao J, Jiang M.   +6 more
europepmc   +1 more source

Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapies have revolutionized the treatment of hematological malignancies, achieving high response rates in patients with relapsed or refractory disease. Despite these benefits, CAR‐T cell therapies are associated with unique toxicities, including cytokine release syndrome (CRS), immune effector cell ...
Livia Donzelli, Veronica Zullino, Giovanni Fernando Torelli, Maria Stefania De Propris, Mario Piazzolla, Franco Ruberto, Maurizio Martelli, Alice Di Rocco   +7 more
wiley   +1 more source

Oncologists' preferences for frontline TKI treatment of Ph+ acute lymphoblastic leukemia: a discrete choice experiment. [PDF]

Future Oncol
Ashaye A, Ramachandran N, Quaife M, Wu Y, Gutiérrez-Vargas ÁA, Jiongco A, Kota V, Savani B, Thomas C.   +8 more
europepmc   +1 more source

18F-FDG PET/CT radiomic analysis with machine learning for identifying bone marrow involvement in the patients with suspected relapsed acute leukemia [PDF]

, 2019
Hao, Keji, Li, Hebei, Wahl, Richard L., Wang, Qian, Wang, Xiuying, Xin, Bowen, Xu, Chongrui, Zhao, Yunyun, Zheng, Chaojie, Zhou, Yun   +9 more
core   +1 more source

Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia

, 2015
Aswathi A. George, Helicia Paz, Fei Fei, Jonathan Kirzner, Yong‐Mi Kim, Nora Heisterkamp, Hisham Abdel‐Azim   +6 more
openalex   +2 more sources

Navigating Solute Carrier Transporters—A Comprehensive Review of Functionalized Small Molecule Probes for Target Identification and Characterization

Medicinal Research Reviews, Volume 46, Issue 1, Page 238-271, January 2026.
ABSTRACT Solute carrier transporters (SLCs) are integral membrane proteins that play pivotal roles in maintaining cellular homeostasis by mediating the transport of a diverse range of substrates across cell membranes. With their involvement in fundamental physiological processes such as nutrient uptake, neurotransmitter signaling, and drug transport ...
Majlen A. Dilweg, Tracie Widjaja, Adriaan P. IJzerman, Daan van der Es   +3 more
wiley   +1 more source

Toll‐Like Receptor Polymorphisms Influence Graft‐Versus‐Host Disease and Infection Risk After Single‐Unit Cord Blood Transplantation for Adults

European Journal of Haematology, Volume 116, Issue 1, Page 37-45, January 2026.
ABSTRACT Background Toll‐like receptors (TLRs) play a critical role in innate immunity by recognizing pathogen‐associated and damage‐associated molecular patterns. Genetic polymorphisms in TLR genes can modulate immune responses and have been implicated in the outcomes of allogeneic hematopoietic cell transplantation (HCT).
Takaaki Konuma, Megumi Hamatani‐Asakura, Seiko Kato, Shohei Andoh, Hirona Ichimura, Junichi Kuroda, Kaori Kondo, Kazuaki Yokoyama, Maki Monna‐Oiwa, Yasuhito Nannya, Satoshi Takahashi   +10 more
wiley   +1 more source

Analysis of adverse reactions and cost-driving factors during the induction phase of pediatric acute lymphoblastic leukemia. [PDF]

Front Pediatr
Xu Z, Jia C, Ding X, Chen X.
europepmc   +1 more source

Chronic Hepatitis B Virus Infection Acquired Under Cytostatic Treatment in Childhood — Clinical, Virological and Immunological Long‐Term Follow‐Up

Journal of Viral Hepatitis, Volume 33, Issue 1, January 2026.
ABSTRACT Oncology patients receiving cytostatic therapy used to be at high risk of HBV infection when HBV screening measures were less reliable. Infections acquired under these conditions often persist, like those acquired perinatally or during early infancy.
Thomas Baumgarten, Felix Lehmann, Tina Senff, Heiko Slanina, Christian G. Schüttler, Andreas Walker, Wolfram H. Gerlich, Reinald Repp, Jörg Timm, Dieter Glebe, Markus Metzler   +10 more
wiley   +1 more source